Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Oceanpine Raises $400 Million for China-US Technology Companies

publication date: Dec 28, 2020

Beijing's Oceanpine Capital closed its Fund II with $400 million for China-US investments in advanced technology, including biopharma companies. Founded in late 2016, Oceanpine used $400 million in capital from general partners for its first fund, including founder Dave Chenn, who built the conglomerate China Century Group. For the second fund, Oceanpine has raised money from external LPs alongside Oceanpine GPs. In the last four years, Oceanpine has invested over $1 billion in over 40 companies using Fund I and other investment vehicles. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital